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To describe macular OCT findings of patients with history of retinopathy of prematurity (ROP) treated with both laser 
and bevacizumab. 
Objective:
Introduction:
Clinical records and OCT (Stratus OCTTM Carl Zeiss Meditec) findings of the first 3 patients treated with both laser 
and bevacizumab at our hospital were reviewed. Control group was comprised by patients that were subject to laser 
treatment and better matched birth weight and gestational age. One eye from each patient was randomly chosen. 
The main outcome measure was foveal and parafoveal retinal thickness.
Methods:
7 eyes of 7 patients with type 1 (stage 3+) disease were studied. All eyes were submited to laser ablation of 
peripheral retina. The 3 patients in bevacizumab group were treated with secondary intra-vitreal injection (0.03mL 
25mg/mL).  Average birth weight was 553± 92g in the bevacizumab group and 802± 43g in the laser group. Average 
gestational age was 25 weeks in the bevacizumab group and 26 weeks in the laser group.
 
Results:
Recent studies in the literature have shown an increased foveal thickness in premature infants with or whithout 
ROP. We report the same findings in our small series of both laser and bevacizumab treated patients. The sample 
was too small to determine hypothetical differences related to treatment modality 
Conclusion:
OCTs at between five and six years of age: 
Patient 4 Patient 5
OCTs at three years of age:
Patient 2Patient 1
Patient 6
Patient 3 Bevacizumab Group Control Group
Mean paravoveal 
thickness (μm) 219 ± 18 256 ± 11
Mean foveal 
thickness (μm) 208 ± 20 243 ± 13
Mean foveal 
depression (μm) 10.7 ± 4.0 13.0 ± 2.7
Patient 7
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Several studies have reported structural eye changes related to prematurity such as steeper corneal curvatures, 
shallower anterior chamber depth and thicker lens. Recently, optical coherence tomography (OCT) has been used 
to study macular changes associated with this condition[1,2]. An increased foveal thickness seems to be an hallmark 
of prematurity. No articles on PubMed report OCT findings of premature infants treated with bevacizumab. 
